期刊文献+

Current therapies for patients with acute exacerbation of idiopathic pulmonary fibrosis 被引量:2

原文传递
导出
摘要 Idiopathic pulmonary fibrosis(IPF)is a chronic,progressive,and generally fatal fibrotic lung disease with a median survival of 2 to 3 years after diagnosis.[1,2]Acute exacerbation of IPF(AE-IPF)is defined as an acute,clinically significant respiratory deterioration characterized by evidence of new widespread alveolar abnormality.Nearly 46%of deaths in IPF are caused by AE-IPF,and the median survival of patients with AE-IPF is approximately 3 to 4 months.[3]Over the past 27 years,great efforts have been paid to find therapies that might work for patients with this condition.We herein summarize current therapies for patients with AE-IPF.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2020年第12期1470-1472,共3页 中华医学杂志(英文版)
基金 This work was supported by grants from the Chinese Academy of Medical Sciences Fund(No.2018-12M-1-001 and No.2019PT320021).
  • 相关文献

同被引文献9

引证文献2

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部